Abstract
We present a single center retrospective case series of four patients with clinically amyopathic dermatomyositis from our institution who were treated with oral sirolimus after failing multiple other therapies. Three out of four patients achieved significant control of disease and were able to decrease their prednisone dose while on sirolimus. There were no clinically significant infections or new malignancies during sirolimus treatment in any of the patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
